Needham Reiterates Buy on Definium Therapeutics, Maintains $66 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.3%

Neg 0% Neu 87.3% Pos 0%

Needham analyst Ami Fadia reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $66 price target.

Comments

No comments yet. Be the first!